U.S. Food and Drug Administration Approves Bristol Myers Squibb ’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news